Proteins Stop Blood-Vessel and Tumor Growth in Mice

	Tweet

Researchers at National Jewish Medical and Research Center report in the March issue of Cancer Research that a pair of promising proteins, known as fibulins 3 and 5, slow the growth of cancer tumors in mice by preventing blood vessels from sprouting. The proteins are promising candidates for use in cancer therapy.

“Healthy humans produce fibulin proteins, which regulate cell proliferation, migration and invasion. In the past, we have seen that they are depleted in numerous metastatic cancers, and that they inhibit the formation of new blood vessels in cell culture,” said William Schiemann, Ph.D., Assistant Professor in the Program in Cell Biology at National Jewish. “Our current findings show that fibulins can inhibit both tumor growth and blood-vessel formation in mice.”

Tumors need nutrients and oxygen supplied by blood vessels in order to grow. They also use blood vessels to spread to other parts of the body. This process, known as metastasis, is the most lethal stage of cancer and the leading cause of cancer-related death. Fighting cancer by starving tumors of life-giving blood vessels has generated great interest in recent years.

In their most recent experiments, Dr. Schiemann and his colleagues injected a biological material, called Matrigel, into mice. The Matrigel contained a growth factor that promotes blood-vessel growth and either a control substance or fibulin 3 or fibulin 5. After seven days, researchers found that the Matrigel plugs containing either fibulin had about half as many blood vessels as did the control plugs.

The researchers then injected fibrosarcoma tumor cells into mice. The tumor cells were genetically engineered to produce either fibulin 3 or fibulin 5. Three weeks after the cells were implanted, developing tumors that produced the fibulins were approximately 24 percent to 45 percent smaller than the control tumors.

“We are thrilled that the fibulins continue to show promise as we move into animal models,” said Dr. Schiemann. “We also found evidence that the fibulins work through more than one biological pathway, which suggests a very robust effect. We further expect the mice to tolerate quite large doses of the fibulins, which makes us hopeful that toxicity will not be a problem.”

The researchers have not yet discovered what receptors the fibulins interact with to produce their anti-angiogenic effect. But in the current paper, they report that the fibulins alter levels of extracellular proteins involved in dissolving and remodeling the extracellular matrix, which can make way for blood-vessel growth.

Moving forward, Dr. Schiemann is working to isolate the portion of the fibulin molecules that actually binds to receptors and causes their biological effect. If they can find a small molecule capable of producing the fibulins’ effects, it would hold more promise as a viable therapy.

RELATED STORIES:
Tiny hitchhikers attack cancer cells   American men with cancer more likely to die than women   Acupuncture Helps Ease Side Effects and Symptoms of Some Cancers   Childhood cancer survivors at increased risk of sarcoma   Cancer survivors at higher risk of mental distress   Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers   Music-based “Play” Helps Young Cancer Patients Cope   Penn Study on Silencing of Tumor Suppressor Gene Suggests New Target for Lymphoma   Study reveals inaccuracies in studies of cancer treatment   Researchers Find Cancer News May Contribute To Confusion About Cancer   Evidence strengthens link between NSAIDs and reduced cancer metastasis   Body Weight, Diet May Be Risk Factors for Non-Hodgkin Lymphoma   Exercise matters long after cancer diagnosis   Two New Studies Back Vitamin D for Cancer Prevention   Insight into the anti-cancer effect of exercise   Deactivating a cancer growth promoter   Berkeley Lab Researchers Illuminate Laminin’s Role in Cancer Formation   Study Predicts Dramatic Growth in Cancer Rates Among U.S. Elderly, Minorities   Cancer detected earlier, faster, with new medical imaging, Stanford study finds   Not all doctors follow cancer screening guidelines   DNA differences may influence risk of Hodgkin disease   Workers in No-Smoking Restaurants Show Lower Carcinogen Levels

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]